voacamine has been researched along with Leishmaniasis, Visceral in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chowdhury, SR; De Macedo Silva, ST; De Souza, W; Dujardin, JC; Godinho, JLP; Kumar, A; Kumari, N; Majumder, HK; Mukhopadhyay, S; Rodrigues, JCF; Roy, S; Saha, S; Sundar, S; Zuma, AA | 1 |
1 other study(ies) available for voacamine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB.
Topics: Animals; Antiprotozoal Agents; Cell Shape; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Enzyme Stability; Female; Ibogaine; Leishmania donovani; Leishmania mexicana; Leishmaniasis, Visceral; Lethal Dose 50; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Plant Bark; Protein Subunits; Recombinant Proteins; Tabernaemontana; Topoisomerase I Inhibitors; Trypanosoma cruzi | 2017 |